A Protein-Binding Molecular Photothermal Agent for Tumor Ablation

Angew Chem Int Ed Engl. 2021 Jun 7;60(24):13564-13568. doi: 10.1002/anie.202101009. Epub 2021 May 6.

Abstract

Photothermal therapy usually requires a high power density to activate photothermal agent for effective treatment, which inevitably leads to damage to normal tissues and inflammation in tumor tissues. Herein, we rationally design a protein-binding strategy to build a molecular photothermal agent for photothermal ablation of tumor. The synthesized photothermal agent can covalently bind to the thiol groups on the intracellular proteins. The heat generated by the photothermal agent directly destroyed the bioactive proteins in the cells, effectively reducing the heat loss and the molecular leakage. Under a low power density of 0.2 W cm-2 , the temperature produced by the photothermal agent was sufficient to induce apoptosis. In vitro and in vivo experiments showed that the therapeutic effect of photothermal therapy can be efficiently improved with the protein-binding strategy.

Keywords: cancer therapy; molecular photothermal agent; photothermal therapy; protein binding; tumor ablation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Humans
  • Lasers
  • Maleimides / chemistry
  • Maleimides / metabolism
  • Maleimides / pharmacology
  • Maleimides / therapeutic use
  • Mice
  • Neoplasms / therapy*
  • Organic Chemicals / chemistry*
  • Organic Chemicals / metabolism
  • Organic Chemicals / pharmacology
  • Organic Chemicals / therapeutic use
  • Photothermal Therapy / methods*
  • Proteins / chemistry*
  • Proteins / metabolism

Substances

  • Maleimides
  • Organic Chemicals
  • Proteins
  • maleimide